BRCA1 and ovarian carcinoma: The identification of BRCA1/2 genes pathogenic alterations in patients suspected to have HBOC, before cancer development or in the first stages of breast and ovarian cancer, grants them the chance to benefit from various medical cancer prevention approaches, such as risk-reducing surgery (mastectomy and salpingo-oophorectomy), chemo-prevention and enhanced surveillance approaches [9].